Two years after submitting the latest version of its insulin pump technology for FDA approval—and three years after it was first made available in Europe—Medtronic has finally secured the agency’s ...
Medtronic has commercially launched its MiniMed 780G system in the US, now integrated with Abbott’s Instinct sensor. The Instinct sensor utilises Abbott’s continuous glucose monitoring (CGM) ...
New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures New data sought to evaluate the MiniMed™ 780G ...
Medtronic (NYSE:MDT) announced on Tuesday that the U.S. FDA cleared its SmartGuard algorithm as an interoperable automated glycemic controller, allowing the integration of its MiniMed 780G insulin ...
The FDA has approved Medtronic’s MiniMed 780G automated insulin delivery (AID) system for use in type 2 diabetes (T2D). At the same time, FDA also cleared the MiniMed SmartGuard algorithm as an ...
Medtronic appears to be circling ever closer to landing the long-awaited FDA clearance for its algorithm-equipped insulin pump—geographically, at least. As of September, the MiniMed 780G system had ...
Medtronic plc MDT has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s ABT Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the ...
A first-of-its-kind meta-analysis comparing multiple automated insulin delivery (AID) systems in people with type 1 diabetes has found that Medtronic's MiniMed 780G achieved the highest time in target ...
Credit: Getty Images. The first shipments of the MiniMed 780G system are expected this summer with preorders beginning on May 15, 2023. The Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback